Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
TRGT's Cash to Debt is ranked higher than
91% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. TRGT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
TRGT' s 10-Year Cash to Debt Range
Min: 11.33   Max: No Debt
Current: No Debt

Equity to Asset 0.96
TRGT's Equity to Asset is ranked higher than
96% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TRGT: 0.96 )
Ranked among companies with meaningful Equity to Asset only.
TRGT' s 10-Year Equity to Asset Range
Min: -5.8   Max: 0.97
Current: 0.96

-5.8
0.97
F-Score: 5
Z-Score: 10.06
M-Score: -3.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -9992.34
TRGT's Operating margin (%) is ranked lower than
93% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. TRGT: -9992.34 )
Ranked among companies with meaningful Operating margin (%) only.
TRGT' s 10-Year Operating margin (%) Range
Min: -10805.09   Max: 15.3
Current: -9992.34

-10805.09
15.3
Net-margin (%) -9829.03
TRGT's Net-margin (%) is ranked lower than
93% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. TRGT: -9829.03 )
Ranked among companies with meaningful Net-margin (%) only.
TRGT' s 10-Year Net-margin (%) Range
Min: -11862.91   Max: 12.72
Current: -9829.03

-11862.91
12.72
ROE (%) -21.52
TRGT's ROE (%) is ranked higher than
55% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. TRGT: -21.52 )
Ranked among companies with meaningful ROE (%) only.
TRGT' s 10-Year ROE (%) Range
Min: -62.37   Max: 13.55
Current: -21.52

-62.37
13.55
ROA (%) -20.52
TRGT's ROA (%) is ranked higher than
52% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. TRGT: -20.52 )
Ranked among companies with meaningful ROA (%) only.
TRGT' s 10-Year ROA (%) Range
Min: -67.26   Max: 3.83
Current: -20.52

-67.26
3.83
ROC (Joel Greenblatt) (%) -5086.41
TRGT's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. TRGT: -5086.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TRGT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5353.87   Max: 22.91
Current: -5086.41

-5353.87
22.91
Revenue Growth (3Y)(%) -85.20
TRGT's Revenue Growth (3Y)(%) is ranked lower than
90% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. TRGT: -85.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TRGT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -85.2   Max: 68.8
Current: -85.2

-85.2
68.8
EBITDA Growth (3Y)(%) 64.80
TRGT's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. TRGT: 64.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TRGT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -79.5   Max: 64.8
Current: 64.8

-79.5
64.8
EPS Growth (3Y)(%) 53.20
TRGT's EPS Growth (3Y)(%) is ranked higher than
93% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. TRGT: 53.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TRGT' s 10-Year EPS Growth (3Y)(%) Range
Min: -92.9   Max: 157.7
Current: 53.2

-92.9
157.7
» TRGT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TRGT Guru Trades in Q2 2014

Jim Simons 29,626 sh (New)
George Soros 13,800 sh (New)
» More
Q3 2014

TRGT Guru Trades in Q3 2014

Jim Simons 34,979 sh (+18.07%)
George Soros Sold Out
» More
Q4 2014

TRGT Guru Trades in Q4 2014

Jim Simons 161,732 sh (+362.37%)
» More
Q1 2015

TRGT Guru Trades in Q1 2015

Jim Simons 256,322 sh (+58.49%)
» More
» Details

Insider Trades

Latest Guru Trades with TRGT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.00
TRGT's P/B is ranked higher than
97% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. TRGT: 1.00 )
Ranked among companies with meaningful P/B only.
TRGT' s 10-Year P/B Range
Min: 0.58   Max: 12.59
Current: 1

0.58
12.59
P/S 374.72
TRGT's P/S is ranked lower than
99% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. TRGT: 374.72 )
Ranked among companies with meaningful P/S only.
TRGT' s 10-Year P/S Range
Min: 0   Max: 376.1
Current: 374.72

0
376.1
EV-to-EBIT 0.59
TRGT's EV-to-EBIT is ranked higher than
96% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. TRGT: 0.59 )
Ranked among companies with meaningful EV-to-EBIT only.
TRGT' s 10-Year EV-to-EBIT Range
Min: -452.3   Max: 48.2
Current: 0.59

-452.3
48.2
Current Ratio 26.96
TRGT's Current Ratio is ranked higher than
94% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. TRGT: 26.96 )
Ranked among companies with meaningful Current Ratio only.
TRGT' s 10-Year Current Ratio Range
Min: 2.15   Max: 37.11
Current: 26.96

2.15
37.11
Quick Ratio 26.96
TRGT's Quick Ratio is ranked higher than
94% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. TRGT: 26.96 )
Ranked among companies with meaningful Quick Ratio only.
TRGT' s 10-Year Quick Ratio Range
Min: 2.15   Max: 37.11
Current: 26.96

2.15
37.11
Days Sales Outstanding 100.08
TRGT's Days Sales Outstanding is ranked lower than
71% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. TRGT: 100.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRGT' s 10-Year Days Sales Outstanding Range
Min: 0.81   Max: 2939.01
Current: 100.08

0.81
2939.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.90
TRGT's Price/Net Cash is ranked higher than
99% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. TRGT: 0.90 )
Ranked among companies with meaningful Price/Net Cash only.
TRGT' s 10-Year Price/Net Cash Range
Min: 0.85   Max: 17.79
Current: 0.9

0.85
17.79
Price/Net Current Asset Value 0.90
TRGT's Price/Net Current Asset Value is ranked higher than
99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. TRGT: 0.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TRGT' s 10-Year Price/Net Current Asset Value Range
Min: 0.85   Max: 16.26
Current: 0.9

0.85
16.26
Price/Tangible Book 0.90
TRGT's Price/Tangible Book is ranked higher than
99% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. TRGT: 0.90 )
Ranked among companies with meaningful Price/Tangible Book only.
TRGT' s 10-Year Price/Tangible Book Range
Min: 0.73   Max: 11.55
Current: 0.9

0.73
11.55
Earnings Yield (Greenblatt) 163.80
TRGT's Earnings Yield (Greenblatt) is ranked higher than
99% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. TRGT: 163.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
TRGT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 2909.5
Current: 163.8

2.1
2909.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HGF.Germany,
Targacept Inc is a biopharmaceutical company engaged incorporated in the year 2001. The Company is engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system. The Company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs, which are found on nerve cells throughout the nervous system and serves as key regulators of nervous system activity. The Company's product candidates are TC-5214, TC-1734, TC-6499, AZD1446 or TC-6683, TC-5619 and TC-6987. It has multiple clinical-stage product candidates and preclinical programs in areas where there are significant medical needs and commercial potential, as well as proprietary drug discovery technologies. It also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. In July 2007, it entered into a product development and commercialization agreement with SmithKline Beecham Corporation, doing business as GlaxoSmithKline, and Glaxo Group Limited. The Company is conducting an ongoing Phase 2b clinical trial of TC-5214. The Company and AstraZeneca are conducting an ongoing exploratory Phase 2 trial of TC-1734 in adults with ADHD. TC-5619 is a novel small molecule that the company plans to develop for cognitive dysfunction in schizophrenia or potentially one or more other conditions characterized by cognitive impairment. TC-5619 modulates the activity of the a7 NNR. AZD1446 or TC-6683 is a novel small molecule that it discovered and advanced as part of the preclinical research collaboration that it is conducting with AstraZeneca. AZD1446 modulates the activity of the a4ß2 NNR and is in development for Alzheimer's disease, ADHD or one or more other conditions characterized by cognitive impairment. The Company is subject to government regulations.
» More Articles for TRGT

Headlines

Articles On GuruFocus.com
Weekly Three-Year Low Highlights: ESIO, VJET, TRGT, ZX May 13 2014 
Why Should You Invest Only in High-Quality Companies? Jun 13 2012 
Seth Klarman Buys 25.5 Million Shares of Global Media Conglomerate Vivendi Apr 17 2012 
Seth Klarman Gives Up Targacept; Sold Out Apr 10 2012 
4 Mar 20 2012 
6 Feb 11 2012 
Seth Klarman Latest Portfolio: Buys IDIX, NG, ANV, Sells PDLI, ALR, BBEP Feb 10 2012 
Seth Klarman Feb 08 2012 
comment on TRGT Dec 28 2011 
comment on TRGT Dec 28 2011 

More From Other Websites
Catalyst Biosciences to Present at the Jefferies 2015 Global Healthcare Conference May 28 2015
TARGACEPT INC Financials May 16 2015
May 14, 2015 Targacept and Catalyst Biosciences Amend Definitive Merger Agreement May 14 2015
TARGACEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... May 14 2015
Targacept and Catalyst Biosciences Amend Definitive Merger Agreement May 14 2015
TARGACEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... May 12 2015
10-Q for Targacept, Inc. May 09 2015
TARGACEPT INC Files SEC form 10-Q, Quarterly Report May 07 2015
10-K for Targacept, Inc. May 03 2015
3 Stocks Under $10 to Trade for Big Breakouts Apr 23 2015
April 16, 2015 Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in... Apr 19 2015
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog Apr 17 2015
Targacept: Gastric Drug Didn't Meet Goals Apr 16 2015
TARGACEPT INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 16 2015
Targacept Announces Negative Top-Line Results from Exploratory Study of TC-6499 in Diabetic... Apr 16 2015
The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead -... Apr 09 2015
Targacept Crumbles as Pfizer Pulls Out of Collaboration - Analyst Blog Apr 07 2015
TARGACEPT INC Files SEC form 8-K, Other Events Apr 06 2015
TARGACEPT INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 17 2015
TARGACEPT INC Files SEC form 10-K, Annual Report Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK